# Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Canonical URL: https://biopharmsignal.com/news/OLMA/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors
Ticker: OLMA
Company: Olema Pharmaceuticals, Inc.
Source: Olema Pharmaceuticals, Inc.
Published: 2026-04-29 20:01 EST
Original Source URL: https://ir.olema.com
## Summary

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the

## Article Body
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the
## Recent Company News
- 2026-05-26 11:00 EST — [Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-evaluate-op-3136-in-combination-with-nubeqar-darolutamide-in-metastatic-castration-resistant-prostate-cancer) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-21 21:00 EST — [Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-12 11:00 EST — [Olema Oncology Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-first-quarter-2026-financial-and-operating-results) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-04 20:30 EST — [Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Olema Pharmaceuticals, Inc.
- 2026-04-29 20:01 EST — [Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors](https://biopharmsignal.com/news/OLMA/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors) — Source: Olema Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)